Premium
First case series on the use of imiquimod for morphoea
Author(s) -
Dytoc M.,
Ting P.T.,
Man J.,
Sawyer D.,
Fiorillo L.
Publication year - 2005
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.2005.06776.x
Subject(s) - medicine , library science , family medicine , geography , computer science
Summary Background Morphoea is characterized by fibrosis, which is mediated by cytokines including transforming growth factor (TGF)‐β. Objective Our objective was to use imiquimod 5% cream (Aldara™), an inducer of interferon‐γ, known to inhibit TGF‐β, to treat morphoea. Methods Patients with morphoea were treated with imiquimod and evaluated during their follow‐up visits to 6 months. Results The dyspigmentation, induration and erythema of 12 patients with morphoea lesions improved. The histology of the skin also showed a decrease in dermal thickness. Conclusion This is the first case series describing the successful application of imiquimod in the management of morphoea.